MustGrow revenue climbs to $8.3 million in 2025 as the company pivots to U.S. market

Canada’s biological and regenerative agriculture solutions provider MustGrow reported a significant increase in revenue for 2025, though losses widened as the company scaled operations and invested in its U.S. expansion strategy. Annual sales reached $8.3 million, up from $0.4 million in 2024, driven primarily by demand for its TerraSante biofertility products. Expenses rose to $7.7 million from $5.4 million a year earlier, largely reflecting the costs associated with operating its NexusBioAg distribution business in Canada. Net losses expanded to $7.3 million, compared with $4.9 million in the prior year.

Growth in the United States was a key contributor, with TerraSante sales reaching $0.6 million, a 377% increase from 2024 levels, supported by demand from retailers and farmers. The company reported a gross margin of 20% for these sales. As of the end of 2025, MustGrow held $0.9 million in cash and equivalents, alongside $2.0 million in inventory. In January 2026, the company raised an additional $2 million through an equity issuance to support operations and expansion.

In April 2026, MustGrow closed its NexusBioAg Canadian distribution division, redirecting resources toward scaling TerraSante production and sales in the U.S. The company said it is working to expand manufacturing capacity and transition to continuous production through contract partners, aiming to improve margins. Management also indicated plans to pursue international commercialization opportunities in markets with potential for expedited regulatory approvals.